Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
The Journal of Headache and Pain
Published in: The Journal of Headache and Pain 1/2014

Open Access 01-12-2014 | Research article

Therapeutic effect of Botulinum toxin-A in 88 patients with Trigeminal Neuralgia with 14-month follow-up

Authors: Shuang Li, Ya-Jun Lian, Yuan Chen, Hai-Feng Zhang, Yun-Qing Ma, Cai-Hong He, Chuan-Jie Wu, Nan-Chang Xie, Ya-Ke Zheng, Yi Zhang

Published in: The Journal of Headache and Pain | Issue 1/2014

Login to get access

Abstract

Background

We investigated the long-term effects and safety of botulinum toxin-A (BTX-A) for treating trigeminal neuralgia (TN). We also studied long-term maintenance of this therapeutic effect.

Methods

A visual analog scale (VAS) score, pain attack frequency per day, patient’s overall response to treatment and side effects during 14-month follow-up were evaluated in 88 patients with TN receiving BTX-A. The primary endpoints were pain severity (assessed by VAS) and pain attack frequency per day. The secondary endpoint was the patient’s overall response to treatment, assessed using the Patient Global Impression of Change. The influence of different doses (≤50, 50–100 and ≥100 U) on the therapeutic effect was evaluated.

Results

Treatment was deemed “effective” within 1 month in 81 patients and at 2 months in 88 patients (100%). The shortest period of effective treatment was 3 months, and complete control of pain was observed in a maximum of 46 patients. The therapeutic effect decreased gradually after 3 months, and the prevalence of effective treatment at 14 months was 38.6%, with complete control of pain seen in 22 patients (25%). There was no significant difference in the prevalence of effective treatment between different dose groups at identical time points (p > 0.05). Three patients showed swelling at injection sites and 10 patients showed facial asymmetry, both of which disappeared spontaneously without special treatment.

Conclusion

Local subcutaneous injection of BTX-A for TN treatment has considerable therapeutic effects lasting several months and is safe for this indication. At least one-quarter of patients maintained complete analgesia. The maintenance period of the therapeutic effect may be related to the reduction in the VAS score after the first injection of BTX-A.
Appendix
Available only for authorised users
Literature
1.
Hall GC, Carroll D, Parry D, McQuay HJ: Epidemiology and treatment of neuropathic pain: the UK primary care perspective [J]. Pain 2006, 122(1–2):156–162.CrossRefPubMed
2.
Lian YJ, Wei HL, Zhang BA, Liu HB, Xu YM, Fang SY, Li ZF, Fang GY, Lu H, Jia YJ, Zhao XY, Wei JK, Zhang L, Song B: Treatment of 795 facial spasm and local dystonia with Botulinum toxin A. J Zhengzhou Univ (Med Sci) 2009, 44(2):440–442.
3.
Bowen ME, Weninger K, Bnmger AT: Single molecule observation of liposome-bilayer fusion thermally induced by soluble Nethyl maleimide sensitive factor attachment protein receptors (SNAREs). Biophys J 2004, 87: 3569–3584.PubMedCentralCrossRefPubMed
4.
Micheli F, Scorticati MC, Raina G: Beneficial effects of botulinum toxin type A for patients with painful tic convulsif. Clin Neuropharmacol 2002, 25: 260–262.CrossRefPubMed
5.
Wu CJ, Lian YJ, Zheng YK: Botulinum toxin type A for the treatment of trigeminal neuralgia: results from a randomized, double-blind, placebo-controlled trial. Cephalalgia 2012, 32: 443–450.CrossRefPubMed
6.
Shen JH, Lian YJ, Zheng YK, Xie YY, Wei HL: Treatment of primary trigeminal neuralgia with botulinum toxin type A. China J Rehabil Med 2011, 26(5):483–484.
7.
Bohluli B, Motamedi MH, Bagheri SC, Bayat M, Lassemi E, Navi F, Moharamnejad N: Use of botulinum toxin A for drug-refractory trigeminal neuralgia: preliminary report. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2011, 111: 47–50.CrossRefPubMed
8.
Zhu TG, Zhang QL, Luo WF, Mao CJ, Hu WD, Liu CF: Clinical treatment of refractory trigeminal neuralgia with botulinum toxin type A. China Clinical Neuroscience 2011, 19(1):32–35.
9.
Gustavo F, Jose DA, Villanueva P, Asensio-Samper JM: Subcutaneous and perineural Botulinum Toxin Type A For Neuropathic Pain. Clin J Pain 2013. [Epub ahead of print]
10.
Xiao L, Mackey S, Hui H, Xong D, Zhang Q, Zhang D: Subcutaneous injection of botulium toxin A is beneficial in postherpetic neuralgia. Pain Med 2011, 11: 1827–1833.CrossRef
11.
Yuan RY, Sheu JJ, Yu JM, Chen WT, Tseng IJ, Chang HH, Hu CJ: Botulinum toxin for diabetic neuropathic pain:a randomized double-blind crossover trial. Neurology 2009, 72: 1456–1478.CrossRef
12.
Taylor M, Silva S, Cottrell C: Botulinum toxin type A in the treatment of occipital neuralgia: a pilot study. Headache 2008, 48: 1476–1481.CrossRefPubMed
13.
Wu CJ, Lian YJ: Botulium toxin type A for trigeminal neuralgia-we have the prima facie evidence. Cephalagia 2012, 32(15):1156–1157.CrossRef
14.
Borodic GE, Acquadro MA: The use of botulinum toxin for the treatment of chronic facial pain. J Pain J Pain 2002, 3: 21–27.CrossRefPubMed
15.
Turk U, Ilhan S, Alp R, Sur H: Botulinum toxin and intractable trigeminal neuralgia. Clin Neuropharmacol 2005, 28: 161–162.CrossRefPubMed
16.
Zuniga C, Diaz S, Piedimonte F, Micheli F: Beneficial effects of botulinum toxin type A in trigeminal neuralgia. Arq Neuropsiquiatr 2008, 66: 500–503.CrossRefPubMed
17.
Aoki KR: Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology 2005, 26: 785–793.CrossRefPubMed
18.
Gazerani P, Pedersen NS, Staahl C, Drewes AM, Arendt-Nielsen L: Subcutaneous botulinum toxin type A reduces capsaicin-indecd trigeminal pain and vasomotor reactions in human skin. Pain 2009, 141: 60–69.CrossRefPubMed
19.
Meng J, Ovsepian SV, Wang J: Activation of TRPV1 mediates calcitonin generelated peptide release, which excites trigeminal sensory neurons and is attenuated by a retargeted botulinum boxin with anti-nociceptive potential. J Neurosci 2009, 29: 4981–4992.CrossRefPubMed
20.
Woolf CJ, Costigan M: Transcriptional and posttranslational plasticity and the generation of inflammatory pain. Proc Natl Acad Sci 1999, 96: 7723–7730.PubMedCentralCrossRefPubMed
Metadata
Title
Therapeutic effect of Botulinum toxin-A in 88 patients with Trigeminal Neuralgia with 14-month follow-up
Authors
Shuang Li
Ya-Jun Lian
Yuan Chen
Hai-Feng Zhang
Yun-Qing Ma
Cai-Hong He
Chuan-Jie Wu
Nan-Chang Xie
Ya-Ke Zheng
Yi Zhang
Publication date
01-12-2014
Publisher
Springer Milan
Published in
The Journal of Headache and Pain / Issue 1/2014
Print ISSN: 1129-2369
Electronic ISSN: 1129-2377
DOI
https://doi.org/10.1186/1129-2377-15-43

Other articles of this Issue 1/2014

The Journal of Headache and Pain 1/2014 Go to the issue

Research article

Use of a fixed combination of acetylsalicylic acid, acetaminophen and caffeine compared with acetaminophen alone in episodic tension-type headache: meta-analysis of four randomized, double-blind, placebo-controlled, crossover studies

Letter to the Editor

Gleaning after the European Headache Federation consensus statement on refractory chronic migraine

Research article

Diagnostic and therapeutic errors in cluster headache: a hospital-based study

Research article

High prevalence of headaches in patients with epilepsy

Editorial

Journal Citation Reports® 2013 tells headache experts that competitive environment has changed

Research article

Expression of 5-HT3 receptors and TTX resistant sodium channels (NaV1.8) on muscle nerve fibers in pain-free humans and patients with chronic myofascial temporomandibular disorders